Hologic (Nasdaq:HOLX) announced today that it now offers its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Novodiag test in Europe.
Marlborough, Massachusetts-based Hologic designed its Panther Fusion and Novodiag (RESP-4 molecular diagnostic) tests detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms in SARS-CoV-2, influenza A and B and respiratory syncytial virus (RSV).
Panther Fusion, a high-performance, cartridge-based assay that runs on the fully automated, high-throughput Panther Fusion system, uses nasopharyngeal swab samples.
Novodiag RESP-4, run on the Novodiag fully automated system, also uses nasopharyngeal swab samples and includes an embedded cellularity control to ensure that the sample was correctly taken, according to a news release.
Hologic’s Panther Fusion portfolio already includes the flu A/B/RSV assay, the Paraflu assay, the AdV/hMPV/RV assay and the Bordetella assay. Novodiag’s assay menu includes diagnostic assays for gastrointestinal infections, hospital-acquired infections, antimicrobial resistance and respiratory infections.
“As we move into the next phase of COVID, it is important that we evolve our assays to support our customers with tests that enable them to differentiate between the multiple respiratory pathogens as easily as possible. The ability to accurately differentiate between respiratory viruses with similar symptoms is essential if physicians are to ensure optimized care for each patient,” Hologic International Group President Jan Verstreken said in the release. “Together, these two assays further build our international offering of molecular diagnostic scalable solutions that meet the growing needs of a broad range of customers, from single-patient rapid testing to population-level screening.”
Novodiag RESP-4 is the first Novodiag assay to be launched since Hologic acquired Mobidiag and the portfolio of Novodiag products for $795 million in June 2021.
